Advanced

Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma

Carlinfante, G; Vassiliou, D; Svensson, O; Wendel, M; Heinegård, Dick LU and Andersson, G (2003) In Clinical and Experimental Metastasis 20(5). p.437-444
Abstract
Breast and prostate cancer often metastasise to the skeleton. Interestingly, the histopathological characteristics of the bone lesions that arise from these two cancer types differ. Breast tumours give rise to metastases in the skeleton with a mixed lytic/sclerotic pattern, whereas a predominantly sclerotic pattern is seen in metastases from prostate tumours. Osteopontin (OPN) and bone sialoprotein (BSP) are bone matrix proteins that have been implicated in the selective affinity of cancer cells for bone. In the present study, 21 patient cases with skeletal metastasis and their respective primary tumours ( 12 with breast cancer, 9 with prostate cancer) were investigated by immunohistochemistry in order to assess the level of OPN and BSP.... (More)
Breast and prostate cancer often metastasise to the skeleton. Interestingly, the histopathological characteristics of the bone lesions that arise from these two cancer types differ. Breast tumours give rise to metastases in the skeleton with a mixed lytic/sclerotic pattern, whereas a predominantly sclerotic pattern is seen in metastases from prostate tumours. Osteopontin (OPN) and bone sialoprotein (BSP) are bone matrix proteins that have been implicated in the selective affinity of cancer cells for bone. In the present study, 21 patient cases with skeletal metastasis and their respective primary tumours ( 12 with breast cancer, 9 with prostate cancer) were investigated by immunohistochemistry in order to assess the level of OPN and BSP. Moderate to strong OPN expression was found in 42% of all breast tumours and in 56% of all prostate tumours. Significantly more breast cancer bone metastases exhibited high OPN expression, 83%, as compared with prostate tumour bone metastases, 11% ( P = 0.0019). In contrast, moderate to strong BSP expression was found in 33% of breast tumours and in 89% of prostate tumours. In the bone lesions, only 33% of breast tumour metastases showed moderate/strong BSP expression compared to 100% of prostate tumour metastases ( P = 0.0046). This divergent pattern of OPN/BSP expression could be an important determinant for the different characteristics of these two types of bone metastasis, i.e., lytic vs. sclerotic, consistent with the proposed role of OPN in differentiation and activation of osteoclasts and of BSP as a stimulator of bone mineralisation. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
bone metastasis, bone sialoprotein, osteopontin
in
Clinical and Experimental Metastasis
volume
20
issue
5
pages
437 - 444
publisher
Springer
external identifiers
  • wos:000184957500007
  • pmid:14524533
  • scopus:0043238919
ISSN
1573-7276
DOI
language
English
LU publication?
yes
id
75d8d307-1d01-4cee-8135-b57ae38688f2 (old id 303584)
date added to LUP
2007-08-27 14:12:29
date last changed
2018-05-29 10:47:05
@article{75d8d307-1d01-4cee-8135-b57ae38688f2,
  abstract     = {Breast and prostate cancer often metastasise to the skeleton. Interestingly, the histopathological characteristics of the bone lesions that arise from these two cancer types differ. Breast tumours give rise to metastases in the skeleton with a mixed lytic/sclerotic pattern, whereas a predominantly sclerotic pattern is seen in metastases from prostate tumours. Osteopontin (OPN) and bone sialoprotein (BSP) are bone matrix proteins that have been implicated in the selective affinity of cancer cells for bone. In the present study, 21 patient cases with skeletal metastasis and their respective primary tumours ( 12 with breast cancer, 9 with prostate cancer) were investigated by immunohistochemistry in order to assess the level of OPN and BSP. Moderate to strong OPN expression was found in 42% of all breast tumours and in 56% of all prostate tumours. Significantly more breast cancer bone metastases exhibited high OPN expression, 83%, as compared with prostate tumour bone metastases, 11% ( P = 0.0019). In contrast, moderate to strong BSP expression was found in 33% of breast tumours and in 89% of prostate tumours. In the bone lesions, only 33% of breast tumour metastases showed moderate/strong BSP expression compared to 100% of prostate tumour metastases ( P = 0.0046). This divergent pattern of OPN/BSP expression could be an important determinant for the different characteristics of these two types of bone metastasis, i.e., lytic vs. sclerotic, consistent with the proposed role of OPN in differentiation and activation of osteoclasts and of BSP as a stimulator of bone mineralisation.},
  author       = {Carlinfante, G and Vassiliou, D and Svensson, O and Wendel, M and Heinegård, Dick and Andersson, G},
  issn         = {1573-7276},
  keyword      = {bone metastasis,bone sialoprotein,osteopontin},
  language     = {eng},
  number       = {5},
  pages        = {437--444},
  publisher    = {Springer},
  series       = {Clinical and Experimental Metastasis},
  title        = {Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma},
  url          = {http://dx.doi.org/},
  volume       = {20},
  year         = {2003},
}